Acorda, Biogen gain on MS drug update
May 20, 2011 at 12:58 PM EDT
Shares of Acorda, Biogen and Elan rise amid a declining market after European regulators move toward approving their MS drug Fampyra.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.